> top > docs > PubMed:32290293 > annotations

PubMed:32290293 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 12-22 SP_7 denotes SARS-CoV-2
T2 90-101 NCBITaxon:11118 denotes coronavirus
T3 103-112 SP_7 denotes 2019-nCoV
T4 126-136 SP_7 denotes SARS-CoV-2
T5 169-173 GO:0040007 denotes grew
T6 242-253 NCBITaxon:11118 denotes coronavirus
T7 263-268 SP_6 denotes human
T8 263-268 NCBITaxon:9606 denotes human
T9 379-392 NCBITaxon:11118 denotes coronaviruses
T10 499-506 GO:0065007 denotes control
T11 647-657 SP_7 denotes SARS-CoV-2
T12 784-794 SP_7 denotes SARS-CoV-2
T13 824-832 SP_10 denotes SARS-CoV
T14 837-881 SP_9 denotes Middle East respiratory syndrome coronavirus
T15 849-860 UBERON:0001004 denotes respiratory
T16 883-891 SP_9 denotes MERS-CoV
T17 1042-1050 SP_7 denotes COVID-19
T18 1083-1093 SP_7 denotes SARS-CoV-2
T19 1094-1100 SO:0001026 denotes genome
T20 1141-1151 GO:0042571 denotes antibodies
T21 1185-1193 CHEBI:75958 denotes solution
T22 1185-1193 CHEBI:75958 denotes solution
T23 1314-1332 CHEBI:52217 denotes therapeutic agents
T24 1314-1332 CHEBI:52217 denotes therapeutic agents
T25 1363-1368 NCBITaxon:10239 denotes virus
T26 1509-1515 CHEBI:36357 denotes agents
T27 1509-1515 CHEBI:36357 denotes agents
T28 1649-1654 NCBITaxon:10239 denotes virus
T29 1649-1654 GO:0006260 denotes virus
T30 1655-1666 GO:0006260 denotes replication
T31 1740-1756 GO:0045087 denotes innate antiviral
T32 1757-1763 UBERON:0002405 denotes immune
T33 1757-1773 GO:0006955 denotes immune responses
T34 1805-1817 GO:0065007 denotes dysregulated
T35 1935-1940 CHEBI:23888 denotes drugs
T36 1935-1940 CHEBI:23888 denotes drugs
T37 1952-1963 CHEBI:119915 denotes favipiravir
T38 1952-1963 CHEBI:119915 denotes favipiravir
T39 1952-1963 DG_17 denotes favipiravir
T40 1952-1963 NCBITaxon:31032 denotes favipiravir
T41 1992-1996 CHEBI:36044 denotes drug
T42 1992-1996 CHEBI:36044 denotes drug
T43 2022-2027 NCBITaxon:10239 denotes viral
T44 2022-2039 GO:0006260 denotes viral replication
T45 2045-2063 CHEBI:5801 denotes hydroxychloroquine
T46 2045-2063 CHEBI:5801 denotes hydroxychloroquine
T47 2045-2063 DG_20 denotes hydroxychloroquine
T48 2080-2092 CHEBI:38068 denotes antimalarial
T49 2080-2092 CHEBI:38068 denotes antimalarial
T50 2093-2097 CHEBI:23888 denotes drug
T51 2093-2097 CHEBI:23888 denotes drug
T52 2123-2128 NCBITaxon:10239 denotes virus
T53 2123-2128 GO:0019012 denotes virus
T54 2129-2138 GO:0005768 denotes endosomal
T55 2129-2144 GO:0035376 denotes endosomal entry
T56 2241-2245 CHEBI:23888 denotes drug
T57 2241-2245 CHEBI:23888 denotes drug

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-55 Sentence denotes A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
T2 56-348 Sentence denotes The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy.
T3 349-525 Sentence denotes Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking.
T4 526-658 Sentence denotes In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2.
T5 659-943 Sentence denotes We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation.
T6 944-1060 Sentence denotes We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic.
T7 1061-1262 Sentence denotes Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety.
T8 1263-1558 Sentence denotes On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety.
T9 1559-1841 Sentence denotes These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses.
T10 1842-2153 Sentence denotes The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway.
T11 2154-2303 Sentence denotes We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.
T1 0-55 Sentence denotes A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
T2 56-348 Sentence denotes The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy.
T3 349-525 Sentence denotes Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking.
T4 526-658 Sentence denotes In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2.
T5 659-943 Sentence denotes We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation.
T6 944-1060 Sentence denotes We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic.
T7 1061-1262 Sentence denotes Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety.
T8 1263-1558 Sentence denotes On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety.
T9 1559-1841 Sentence denotes These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses.
T10 1842-2153 Sentence denotes The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway.
T11 2154-2303 Sentence denotes We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.